Health Economics of Substance Use Disorder, HCV, and HIV Treatment in the Era of Integrated Health Care

综合医疗保健时代药物滥用、丙型肝炎和艾滋病毒治疗的卫生经济学

• 批准号: 9506377
• 负责人: Bruce R Schackman
• 金额: $ 10万
• 依托单位: WEILL MEDICAL COLL OF CORNELL UNIV
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-09-01 至 2018-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9506377
• 关键词: Address; Affordable Care Act; Alcohol or Other Drugs use; American; Award; Caring; Clinical; Clinical Trials; Collaborations; Communication; Consultations; Costs and Benefits; Data; Data Collection; Development; Discipline; Economics; Ensure; Environment; Feedback; Funding; Grant; HIV; HIV/HCV; Health; Health Insurance; Health Personnel; Healthcare; Healthcare Systems; Hepatitis C; Individual; Institution; Insurance Carriers; Insurance Coverage; Intervention; Leadership; Location; Mental Health; Mentors; Mentorship; Methodology; Methods; Observational Study; Online Systems; Organizational Models; Pattern; Persons; Pharmaceutical Preparations; Policies; Process; Provider; Research; Research Infrastructure; Research Personnel; Research Project Grants; Research Support; Resources; Self-Examination; Services; Structure; Substance Use Disorder; System; Technology; Time; Training; Training Activity; Translating; United States National Institutes of Health; Work; advanced simulation; career development; clinically relevant; cohort; dissemination research; economic evaluation; economic impact; economic need; experience; health economics; improved; innovation; meetings; models and simulation; novel; outreach; parity; public health relevance; ranpirnase; research data dissemination; screening; simulation; skills; sound; tool; training opportunity; treatment strategy; Address; Affordable Care Act; Alcohol or Other Drugs use; American; Award; Caring; Clinical; Clinical Trials; Collaborations; Communication; Consultations; Costs and Benefits; Data; Data Collection; Development; Discipline; Economics; Ensure; Environment; Feedback; Funding; Grant; HIV; HIV/HCV; Health; Health Insurance; Health Personnel; Healthcare; Healthcare Systems; Hepatitis C; Individual; Institution; Insurance Carriers; Insurance Coverage; Intervention; Leadership; Location; Mental Health; Mentors; Mentorship; Methodology; Methods; Observational Study; Online Systems; Organizational Models; Pattern; Persons; Pharmaceutical Preparations; Policies; Process; Provider; Research; Research Infrastructure; Research Personnel; Research Project Grants; Research Support; Resources; Self-Examination; Services; Structure; Substance Use Disorder; System; Technology; Time; Training; Training Activity; Translating; United States National Institutes of Health; Work; advanced simulation; career development; clinically relevant; cohort; dissemination research; economic evaluation; economic impact; economic need; experience; health economics; improved; innovation; meetings; models and simulation; novel; outreach; parity; public health relevance; ranpirnase; research data dissemination; screening; simulation; skills; sound; tool; training opportunity; treatment strategy

 DESCRIPTION (provided by applicant): The US healthcare system is evolving towards a more integrated approach to improving the health of Americans. Greater availability of health insurance through the Affordable Care Act and new organizational models such as integrated healthcare systems are leading health care providers and insurers to consider the totality of costs and benefits, instead of focusing on costs and benefits of individual service delivery "silos." For substance users, parity requirements for substance use disorder (SUD) and mental health insurance coverage and health insurance expansion present new opportunities for integrated care. They also present new opportunities and challenges for treating HCV-infected and HIV-infected substance users with highly effective and expensive medications. Both the broad societal economic impact and the health economic benefits for individuals of SUD, HCV, and HIV treatment need to be evaluated and communicated to clinical and policy decision makers in the context of this new environment. The overall specific aim of our P30 Center of Excellence proposal entitled "Health Economics of Substance Use Disorder, HCV, and HIV Treatment in the Era of Integrated Health Care" is to develop and disseminate economic evidence that informs substance use treatment policy and HCV and HIV care of substance users, and to increase the impact of this research by addressing the needs of integrated healthcare system providers and payers. Our proposed Center (CHERISH: Center for Health Economics of Treatment Interventions for Substance Use Disorder, HCV, and HIV) includes Methodology, HCV and HIV, Dissemination and Policy, Pilot Grant and Training, and Administrative Cores, a Policy Advisory Board, and a Center Advisory Board. The Core leaders and investigators have extensive experience with multi-institutional collaborations and several previous and ongoing collaborations. They will draw on a wider circle of experts involved with each of the NIH-supported research projects. CHERISH will be led by an established national expert in SUD, HCV, and HIV health economic research who has substantial management experience. We will innovatively use web-based technology to supplement frequent in-person meetings and support a structured management process and administrative tracking system. The proposed Center will serve as a national SUD health economics research resource, furthering scientific collaborations among researchers, providing feedback to these researchers from stakeholders, and conducting outreach to clinical and policy decision makers. Such interaction between researchers and decision makers is essential for NIH-funded research on SUD treatment strategies to have its greatest impact. Through pilot grants and associated training activities, we will provide new opportunities for training, mentoring and career development for researchers in the field of SUD, HCV, and HIV health economics. These activities will yield a new cohort of investigators with the skills needed to conduct methodologically sound and innovative SUD economic research to inform SUD, HCV, and HIV treatment policy.

 描述（由适用提供）：美国医疗保健系统正在发展为改善美国人健康的更综合方法。通过《平价医疗法案》和新的组织模式（例如综合医疗保健系统）提供了更大的健康保险，领导医疗保健提供者，并确保考虑成本和福利的总体，而不是专注于个人服务交付“ Silos”的成本和收益。对于药物使用者，药物使用障碍（SUD）和心理健康保险范围和健康保险扩展的均等要求为综合护理提供了新的机会。他们还提出了新的机遇和挑战，以使用高效且昂贵的药物治疗HCV感染和HIV感染的药物使用者。在这种新环境的背景下，需要评估广泛的社会经济影响以及对SUD，HCV和HIV治疗个人的健康经济益处。我们P30卓越中心提案的总体具体目的为“在综合卫生保健时代的健康经济学，HCV和HIV治疗的健康经济学”是为了开发和传播经济证据，这些证据向药物治疗政策以及HCV和HIV的毒品用户提供信息，并通过解决这项研究的影响来通过满足整体保健系统的薪水的需求来增加这项研究的影响。我们提议的中心（珍贵：针对药物使用障碍，HCV和HIV的治疗干预措施的健康经济学中心）包括方法论，HCV和HIV，传播和政策，试点赠款和培训以及行政核心，政策顾问委员会和中心顾问委员会。核心领导者和调查人员在多机构合作以及以前和正在进行的几次合作方面都有丰富的经验。他们将利用与NIH支持的每个研究项目有关的众多专家。珍惜将由拥有丰富管理经验的SUD，HCV和HIV健康经济研究领域成熟的国家专家领导。我们将创新使用基于Web的技术来补充面对面的会议，并支持结构化的管理过程和管理跟踪系统。拟议的中心将作为国家SUD健康经济学研究资源，研究人员之间的进一步科学合作，从利益相关者那里向这些研究人员提供反馈，并向临床和政策决策者进行宣传。研究人员与决策者之间的这种相互作用对于NIH资助的SUD治疗策略的研究至关重要。通过试点赠款和相关培训活动，我们将为SUD，HCV和HIV健康经济学领域的研究人员提供新的培训，心理和职业发展机会。这些活动将产生一系列新的研究人员，具有开展方法论和创新的SUD经济研究所需的技能，以告知SUD，HCV和HIV治疗政策。